VVUS 3.14 Vivus Inc $VVUS Hit a 52 week low of 3.13 Closing

New Post Public Reply Private Reply Replies (0) Message Board
Emylers
VVUS 3.14 Vivus Inc $VVUS Hit a 52 week low of 3.13 Closing the day 10:45 at 3.14 -0.11 -3.38% With a day low of 3.13 and a total volume of 737,204.

VVUS Recent Posts: http://investorshangout.com/VIVUS-Inc-VVUS-55858/

VVUS Vivus Inc Recent Headline News

ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST

OREX: 5.58 (-0.07), HLF: 38.48 (-0.02), NVO: 43.73 (-0.40), VVUS: 3.13 (-0.12), AMGN: 158.64 (+0.96), GSK: 45.82 (+0.08), ARNA: 4.55 (+0.02)

Critical Alerts For American Eagle Outfitters, Novartis, VIVUS, King Digital and Canadian Solar Released By InvestorsObserver
PR Newswire - Thu Nov 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AEO, NVS, VVUS, KING and CSIQ.
AEO: 13.44 (-0.06), VVUS: 3.13 (-0.12), CSIQ: 26.11 (-0.82), KING: 15.79 (-0.33), NVS: 94.41 (+0.46)

Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST

OREX: 5.58 (-0.07), VVUS: 3.13 (-0.12), ARNA: 4.55 (+0.02)

Orexigen Turns Around with Q3 Earnings Beat, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:20AM CST
Orexigen (OREX) swung to profit in the third quarter of 2014 with earnings of 9 cents per share beating the Zacks Consensus Estimate of 5 cents.
OREX: 5.58 (-0.07), VVUS: 3.13 (-0.12), AMAG: 34.83 (+0.83)

Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically,  Arena Pharmaceuticals '   Belviq and  VIVUS 's   Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 29.95 (-0.39), VVUS: 3.13 (-0.12), GSK: 45.82 (+0.08), ARNA: 4.55 (+0.02)

Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 5.58 (-0.07), VVUS: 3.13 (-0.12), ARNA: 4.55 (+0.02)

Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST

OREX: 5.58 (-0.07), VVUS: 3.13 (-0.12), ARNA: 4.55 (+0.02)

Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.58 (-0.07), VVUS: 3.13 (-0.12), ARNA: 4.55 (+0.02)

3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.13 (-0.12), SNY: 47.29 (+0.61), GNW: 9.32 (-0.09), REGN: 403.37 (+8.17)

Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST

VVUS: 3.13 (-0.12), ARNA: 4.55 (+0.02)

VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:45PM CST
VIVUS Inc.'s (VVUS) third-quarter 2014 loss of 11 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 21 cents.
AUXL: 32.31 (+0.14), VVUS: 3.13 (-0.12), AMAG: 34.83 (+0.83), SNY: 47.29 (+0.61)

Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST

OREX: 5.58 (-0.07), VVUS: 3.13 (-0.12), ARNA: 4.55 (+0.02)

Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST

VVUS: 3.13 (-0.12), ARNA: 4.55 (+0.02)

VIVUS' (VVUS) CEO Seth Fischer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 6:18PM CST

VVUS: 3.13 (-0.12)

Vivus tops Street 3Q forecasts
Automated Insights - Wed Nov 05, 4:45PM CST
MOUNTAIN VIEW, Calif. (AP) _ Vivus Inc. (VVUS) on Wednesday reported a third-quarter loss of $15.8 million.
VVUS: 3.13 (-0.12)

Vivus Q3 revenues up 24%
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:29PM CST

VVUS: 3.13 (-0.12)

Vivus (VVUS) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST

VVUS: 3.13 (-0.12)

Vivus beats by $0.10, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:03PM CST

VVUS: 3.13 (-0.12)

VIVUS Reports Third Quarter 2014 Financial Results
Marketwired - Wed Nov 05, 3:02PM CST
VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the third quarter ended September 30, 2014 and provided a business update.
VVUS: 3.13 (-0.12)

Vivus reports today
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:12AM CST

VVUS: 3.13 (-0.12)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Pioneers eATA Carnet System Beyond Europe

Updated Category News Views 139

Breaking Tradition with Digital Innovation Well, who would’ve thought? The UAE just leapt ahead in the trade game, becoming the first to roll out the eATA Carnet system beyond the cozy confines of Europe. This isn’t some run-of-the-mill tech rollout, folks. It’s a digital revolution in how temporary imports are handled—goodbye paper, hello efficiency! With this...

Continue Reading
Valve Tool Innovation Streamlines Hydraulic Maintenance

Updated Category News Views 17

A New Gadget Promises Big Savings in Time and Effort Ever wrestled with a hydraulic hose and felt like you were arm wrestling a gorilla? Well, it looks like there's a new gadget on the scene that might save you from that struggle. Straight from Menomonie, Wisconsin, we’ve got a slick new tool hitting the market called THE VALVE TOOL. The idea is simple but effective:...

Continue Reading
Tax Planning vs. Preparation: Strategic Differences

Updated Category News Views 8

Tax Strategy: Not All About April 15 Ready to fend off that taxman? Well, don’t just wait for that dreaded April deadline. Greg Harrison over at Harrison Financial Management spills some wisdom on the oft-overlooked nuances between tax planning and tax preparation. It’s not just semantics; it’s the difference between shaping your financial future and simply...

Continue Reading
Wendy C. Wilson Earns Inner Circle Pinnacle Honor

Updated Category News Views 77

Leadership Recognized: Wendy C. Wilson's Impact Some folks know their way around the trenches of corporate battle, and Wendy C. Wilson is one of them. Known for her grit and savvy, she now takes a coveted spot in The Inner Circle of Excellence as a Pinnacle Professional Member. This title isn't just for show—it's a hat tip to her powerhouse contributions as a speaker on...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 196

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
Expedera Teams Up with Cadence for Edge AI Supercharge

Updated Category News Views 57

A New Power Couple in AI Expedera and Cadence have decided to stir up the edge AI waters with their latest collaboration. By linking Expedera's Origin™ Evolution NPU with Cadence's Tensilica NeuroEdge 130 AI Co-Processor, we're looking at a partnership that's hell-bent on redefining efficiency and performance in edge AI systems. Breaking Down the Collaboration This...

Continue Reading
Foundayo Aims to Revolutionize Sleep Apnea Treatment

Updated Category News Views 81

Revolution in Sleep Health The paper has officially announced a promising shift in sleep apnea treatment. Eli Lilly's Foundayo, revealed through a Phase 3 clinical program, is looking to tackle obstructive sleep apnea (OSA) with unprecedented potential. Forget the traditional methods—this small molecule GLP-1 receptor agonist could be a game changer for folks plagued by...

Continue Reading
Segway Powersports Ventures into Baja 1000: Ambitions Run High

Updated Category News Views 149

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

Continue Reading
Century Lithium's Angel Island Project Nears NEPA Review

Updated Category News Views 67

Sometimes the gears of progress grind slowly, but that's part of the deal in the mining game. For Century Lithium Corp., the completion of the Mine Plan of Operations (PoO) for the Angel Island Project marks a big step forward—or at least, it gets them ready for the next round of bureaucratic wrangling under the NEPA. Let's dissect what this means as they march toward...

Continue Reading
Laboratoires Pierre Fabre and XtalPi Unite for AI-Driven Drug Hunt

Updated Category News Views 197

An Unexpected Turn in the Drug Discovery Arena It's not every day that you see a historic French pharma powerhouse and a cutting-edge Chinese tech firm join forces. On one side, we've got Laboratoires Pierre Fabre, steeped in the history and nitty-gritty of clinical drug development. On the other, we’ve got XtalPi Holdings Limited (2228.HK), bringing their high-tech AI...

Continue Reading

Top 5 Most Recently Viewed Articles

Novartis and NFL Stars Unite for Prostate Cancer Awareness

Updated Category News Views 168

Novartis Collaborates with NFL Legends for Health Awareness In an inspiring partnership, several NFL icons, including Coach Bruce Arians, Rob Gronkowski, and George Kittle, are joining forces with Novartis to elevate awareness about prostate cancer screening. Their initiative is particularly significant as statistics reveal that one in eight men will encounter this...

Continue Reading
MassageLuXe Celebrates 100th Spa and Expands Franchise Network

Updated Category News Views 192

MassageLuXe Celebrates 100th Location Milestone MassageLuXe, a prominent luxury spa franchise renowned for its exceptional massage therapy and skincare services, recently marked an impressive milestone with the grand opening of its 100th spa. This achievement not only highlights the brand's significant growth but also reflects its commitment to enhancing wellness in...

Continue Reading
Women's Workforce Progress: Gains and Challenges Ahead

Updated Category News Views 268

Analyzing Women's Workforce Gains and Ongoing Challenges Five years following the pandemic, women's employment has surged to unprecedented levels, while men are increasingly engaging in unpaid caregiving roles. However, significant disparities remain—particularly for mothers and women of color—alluding to the necessity of maintaining this positive momentum and seeking...

Continue Reading
Market Insights: Man Group PLC's Engagement with American Axle

Updated Category News Views 131

Understanding Man Group PLC's Position Man Group PLC is a distinguished player in the investment management landscape. With a robust portfolio and a commitment to innovative strategies, they have established a strong presence in various sectors, including automotive manufacturing. Their recent engagement with American Axle & Manufacturing Holdings Inc. showcases their...

Continue Reading
CVC Challenges Deutsche Bahn's Decision on Schenker Sale

Updated Category News Views 129

CVC Questions Deutsche Bahn's Schenker Sale Decision In a noteworthy development, CVC, a financial investor, is stepping up to impact the sale of Schenker, the logistics division currently owned by Deutsche Bahn. A recent letter reveals CVC’s strong position, urging the German state railway to reconsider its $16 billion deal with Denmark's DSV. This communication raises...

Continue Reading